Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease

This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> (MAP), long considered a putative cause, would favorably affect Crohn’s disease...

Full description

Bibliographic Details

Published in:	Antibiotics
Main Authors:	David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
Format:	Article
Language:	English
Published:	MDPI AG 2024-07-01
Subjects:	RHB-104 Crohn’s disease <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> clinical trial clarithromycin rifabutin
Online Access:	https://www.mdpi.com/2079-6382/13/8/694